ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2025
Electroacupuncture alleviates type 2 diabetes mellitus by promoting plasma-derived exosomal circular RNA of enhancer of zeste homolog 1 expression.
Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Acupuncture-driven exosomes: an emerging therapy.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026Review
- Circular RNAs as diagnostic biomarkers in type 2 diabetes mellitus: implications in metabolic dysfunction and immune-inflammatory crosstalk.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo investigate the effect of electroacupuncture (EA) on regulatory functions of one specific exosomal circRNA of Enhancer of Zeste Homolog (CircEZH) and its potential mechanisms of action in type 2 diabetes (T2DM).
methodsMice were fed a high-fat diet (HFD) and intraperitoneally injected with streptozotocin to create the T2DM model and then were used for two experiments involving the following groups: experiment 1 (control group, T2DM group, T2DM+EA group, 10 mice per group) and experiment 2 [control group, T2DM group, T2DM+ CircEZH1-siRNA (20 nmol/20 g) group, 10 mice per group]. Exosomal size, distribution, and morphology were evaluated
resultsEA treatment significantly reduced the serum insulin level and cell apoptosis in pancreatic tissue in a T2DM model. EA treatment markedly upregulated CircEZH1 expression in the exosomes of T2DM mice. Further study showed that CircEZH1 overexpression resulted in increased Min6 cell viability and decreased Min6 cell apoptosis when compared with the levels in an overexpression control group. In Min6 cells with CircEZH1 knockout, the opposite trends were identified. CircEZH1-knockout Min6 cells also showed reduced insulin expression.
conclusionsEA can affect CircEZH1 expression specifically in the exosomes in β cells in the pancreatic islets to improve T2DM. Exosomal CircEZH1 is a potential therapeutic candidate to treat T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.